Inhibitors for Protein alpha-N-terminal Methyltransferases

Back to all technologies
Download as PDF
Protein N-terminal methyltransferase 1 (NTMT1) plays an important role in regulating cell mitosis, chromatin interactions, and DNA repair. NTMT1 is over-expressed in cancer patient tissues including the head and neck, colorectal, malignant melanoma, compared to normal tissue. Knockdown of NTMT1 promotes hypersensitivity of breast cancer cell lines to double-strand DNA breaks (DSBs) by etoposide and gamma irradiation. This knowledge has made NTMT1 an important anticancer target. Currently, there are no specific cell-potent probes available for NTMT1. There is a need for a new technology that can target the NTMT1 protein.

Researchers at Purdue University have developed new potent inhibitors for the protein NTMT. The inhibitor exhibited high selectivity to NTMT1/2 over a panel of 41 methyltransferases. These chemical compounds are novel because they are amenable for cell-based studies. They may be further optimized for animal studies. This technology is more stable and cell-permeable than existing solutions. This technology could open the door for elucidate the pharmacological functions of protein NTMT1.

-Amenable for cell based studies
-Displays selective inhibition for NTMT1
-May be used for animal studies

Potential Applications:
-Cell based studies
-Animal studies
May 16, 2019
Utility Patent
United States

May 17, 2018
United States
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486